Intelligent OMICS Ltd (Intellomx), a leading biotechnology company based at BioCity Nottingham, today announced a target discovery collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The partnership will help to evaluate novel biological targets for the treatment of haematological cancers. The agreement was facilitated by Johnson & Johnson Innovation.
The collaboration will also combine Intellomx’s proprietary AI platform, which integrates multi-omics data and deep learning algorithms to uncover novel disease mechanisms and therapeutic opportunities for treatment, with Janssen’s expertise in data science, oncology research and development.
“We are thrilled to be working with Janssen and their oncology discovery and data science experts to apply our AI platform to haematological cancers, which are among the most challenging and complex diseases to treat,” said Dr Robert Grundy, CEO of Intellomx. “We believe that our AI platform can generate novel insights into the molecular drivers of these cancers and identify new ways to intervene therapeutically.”
Under the terms of the agreement, Intelligent OMICS will receive an upfront payment and research support from Janssen, as well as potential milestone payments based on the successful development of products resulting from the collaboration.
About Intelligent Omics Ltd
Intelligent Omics Ltd is a leading UK-based drug discovery company that interrogates network biology with AI to discover biological targets that drive disease. The company solves a crucial large pharma problem: “Where do we find the next blockbuster drug?”. The BioCity Nottingham-based company strive to solve this faster and more economically than has ever been possible.
For more information about Intelligent Omics Ltd, please visit https://www.intellomx.com/.